Anastrozole
Targets non-steroidal reversible type ii aromatase (cyp19a1) inhibitor pathways to control symptoms and support evidence-based outpatient management.
Bioidentical T4/T3 thyroid hormone replacement, transdermal menopause HRT patches, micronized progesterone, and androgen/SERM protocols.
Toggle your prescriptions and supplements below to see stomach mineral absorption blocks, CYP450 conflicts, and your exact 24-hour clock:
Take 30–60 min before coffee/breakfast; keep 4 hours away from Iron, Calcium & Magnesium.
Alternate-day morning dosing with 200 mg Vitamin C avoids the 24h hepcidin block and protects Levothyroxine.
Avoid potassium chloride salt substitutes or high-dose potassium supplements (hyperkalemia >5.2 mEq/L risk).
Fat-soluble D3, K2 (MK-7), Omega-3 rTG, and CoQ10 Ubiquinol absorb 32%–50% better with dietary fat.
Taking Extended-Release (ER) mid-dinner cuts GI nausea/diarrhea by >60%. Check Vitamin B12 + MMA yearly.
Pairs cleanly with dinner alongside CoQ10 Ubiquinol (100–200 mg) to support muscle mitochondrial ATP.
Safely separated 15 hours from morning Levothyroxine; glycine + Mg2+ support GABAergic deep sleep.
Never pay a $45–$68 retail pharmacy walk-in markup for pennies-per-pill generics:
Targets non-steroidal reversible type ii aromatase (cyp19a1) inhibitor pathways to control symptoms and support evidence-based outpatient management.
Targets long-acting lactotroph dopamine d2-receptor agonist pathways to control symptoms and support evidence-based outpatient management.
Regulates follicular keratinization, sebum production, or scalp DHT activity over 8–16 weeks.
Targets mixed selective estrogen receptor modulator (serm) pathways to control symptoms and support evidence-based outpatient management.
Targets hypothalamic estrogen receptor antagonist / gonadotropin secretagogue pathways to control symptoms and support evidence-based outpatient management.
Targets selective non-antiandrogenic mineralocorticoid receptor antagonist pathways to control symptoms and support evidence-based outpatient management.
Targets secosteroid nuclear vitamin d receptor (vdr) prohormone repletion pathways to control symptoms and support evidence-based outpatient management.
Reduces menopause hot flashes and night sweats by 80%–90% within 2–4 weeks while preserving lumbar bone mineral density.
Restores euthyroid T4/T3 hormone reservoirs over a 6-week steady-state equilibration (7-day half-life) to normalize TSH and energy.
Targets direct nuclear thyroid hormone receptor agonist (active t3) pathways to control symptoms and support evidence-based outpatient management.
Targets endometrial progesterone receptor agonist & allopregnanolone neurosteroid precursor pathways to control symptoms and support evidence-based outpatient management.
Targets benzothiophene bone-agonist / breast-antagonist serm pathways to control symptoms and support evidence-based outpatient management.
Regulates follicular keratinization, sebum production, or scalp DHT activity over 8–16 weeks.
Targets esterified parenteral androgen receptor agonist pathways to control symptoms and support evidence-based outpatient management.
Targets natural porcine thyroglobulin t4 + t3 combination pathways to control symptoms and support evidence-based outpatient management.
Targets parathyroid hormone-related peptide analog pathways to control symptoms and support evidence-based outpatient management.
Targets androgen receptor inhibitor pathways to control symptoms and support evidence-based outpatient management.
Targets gonadotropin pathways to control symptoms and support evidence-based outpatient management.
Targets estrogen agonist/antagonist pathways to control symptoms and support evidence-based outpatient management.
Targets androgen pathways to control symptoms and support evidence-based outpatient management.
Targets gonadotropin releasing hormone receptor antagonist pathways to control symptoms and support evidence-based outpatient management.
Targets androgen receptor inhibitor pathways to control symptoms and support evidence-based outpatient management.
Targets estrogen pathways to control symptoms and support evidence-based outpatient management.
Targets estrogen pathways to control symptoms and support evidence-based outpatient management.
Targets localized genitourinary mucosal estrogen trophy restorer pathways to control symptoms and support evidence-based outpatient management.
Targets progestin pathways to control symptoms and support evidence-based outpatient management.
Targets aromatase inhibitor pathways to control symptoms and support evidence-based outpatient management.
Targets androgen receptor inhibitor pathways to control symptoms and support evidence-based outpatient management.
Targets gonadotropin pathways to control symptoms and support evidence-based outpatient management.
Targets estrogen receptor antagonist pathways to control symptoms and support evidence-based outpatient management.
Targets gonadotropin releasing hormone receptor antagonist pathways to control symptoms and support evidence-based outpatient management.
Targets gonadotropin releasing hormone receptor agonist pathways to control symptoms and support evidence-based outpatient management.
Targets gonadotropin releasing hormone receptor agonist pathways to control symptoms and support evidence-based outpatient management.
Targets progestin pathways to control symptoms and support evidence-based outpatient management.
Targets estrogen pathways to control symptoms and support evidence-based outpatient management.
Lowers atherogenic LDL-C and ApoB particles within 4–6 weeks to reduce arterial plaque progression.
See exact ACC/AHA blood pressure stages, ADA HbA1c thresholds, and step-up treatment ladders across 40 specialty hubs.
Check when statins, Metformin, or PPIs deplete CoQ10, Vitamin B12, or Magnesium—and how to decode elemental supplement labels.
Find board-certified endocrinologists, cardiologists, and internists verified by CMS Medicare Part B volume and accepted insurance plans.
dotMD.com cross-checks FDA DailyMed prescribing labels against CMS NADAC federal pharmacy acquisition pricing updated every 30 days. Generic retail quotes regularly run 8x to 40x above wholesale ($0.45–$2.85 per 30 days), letting patients compare transparent cash pricing, ER vs. IR tolerability, and boxed warnings with 0% pharma sponsorship.
| Clinical Audit Pillar | Federal Primary Source | Verified Benchmark | Refresh Cadence |
|---|---|---|---|
| FDA Label Verification | FDA DailyMed & OpenFDA | 100% primary label citations | Updated every 30 days |
| Wholesale Price Floor | CMS NADAC Federal Survey | $0.45–$2.85 typical 30-day generic | 8x–40x below cash retail |
| Tolerability & Timing | PubMed Phase 3–4 Trials | Up to 50% GI drop with ER/food | Verified trial cohorts |
| Safety & Monitoring | FDA FAERS & Guidelines | Kidney, liver & B12 lab cutoffs | Every 90–180 days |
dotMD.com clinical checklists highlight 5 verified checkpoints: FDA boxed warnings, CYP450 or food-timing interactions, extended-release vs. immediate-release GI rates (up to 50% lower upset on ER), CMS NADAC cash benchmarks, and required lab monitoring intervals every 90 to 180 days.
Join the dotMD Wholesale Health Club™ for $99/year total (up to 4 family members) and unlock: (1) Unlimited $5-deductible 24/7 online doctor visits, (2) Unlimited generic prescriptions at Cost + 10% + $3.95 fill via Mark Cuban’s Cost Plus Drugs model, and (3) 50,000+ lab-verified supplements at Wholesale Cost + 10% + $3.95 fill.